Table 2. Summary data for physiological measures during 21-km running while ingesting either CEPS, CES or PLA.
Main effects of treatments | Pre-exercise | 5-km | 10-km | 15-km | Post-exercise | ||
---|---|---|---|---|---|---|---|
Glucose (mmol/L) | CEPS | CES vs. PLA (P<0.05) | 5.81 ± 1.65 | 4.83 ± 0.87 | 4.83 ± 1.18 | 5.01 ± 0.64a | 4.38 ± 1.23 |
CES | 5.92 ± 0.95 | 5.17 ± 0.78b | 5.49 ± 1.33 | 5.43 ± 1.06b | 5.62 ± 1.10b | ||
PLA | 5.64 ±0.93 | 4.33 ± 0.46 | 4.24 ± 0.87 | 4.14 ± 0.67 | 3.88 ± 1.08 | ||
Lactate (mmol/L) | CEPS | 1.26 ± 0.48 | 2.04 ± 1.23 | 2.23 ± 0.96 | 2.03 ± 0.82 | 2.34 ± 0.81 | |
CES | 1.26 ± 0.45 | 1.89 ± 0.78 | 2.95 ± 1.84 | 2.61 ± 1.38 | 3.29 ± 1.64 | ||
PLA | 1.28 ± 0.75 | 1.91 ± 0.76 | 2.07 ± 0.89 | 1.69 ± 0.64 | 1.98 ± 1.20 | ||
HR (beats/min) | CEPS | 67 ± 13 | 151 ± 21 | 153 ± 14 | 157 ± 17 | 163 ± 15 | |
CES | 69 ± 13 | 150 ± 12 | 163 ± 14 | 160 ± 16 | 165 ± 17 | ||
PLA | 65 ± 11 | 146 ± 14 | 153 ± 14 | 152 ± 15 | 155 ± 13 | ||
RER (VCO2/VO2) | CEPS | 0.93 ± 0.09 | 0.90± 0.05 | 0.90± 0.05 | 0.90± 0.05a | 0.89± 0.05a | |
CES | 0.88± 0.05 | 0.88± 0.06 | 0.88± 0.07 | 0.87± 0.07 | 0.86± 0.06 | ||
PLA | 0.87± 0.05 | 0.89± 0.04 | 0.88± 0.03 | 0.86± 0.04 | 0.83± 0.05 |
a P<0.05, CEPS vs. PLA;
bP<0.05, CES vs. PLA.
CEPS: Carbohydrate-electrolyte-protein solution; CES: Carbohydrate-electrolyte solution; PLA: Placebo.